0000000001191238

AUTHOR

A A

showing 2 related works from this author

Elective Cancer Surgery in COVID-19-Free Surgical Pathways during the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study

2020

PURPOSE As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19–free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a …

MaleCancer ResearchOutcome AssessmentInternational CooperationSettore MED/18 - CHIRURGIA GENERALESettore MED/19 - Chirurgia Plastica030230 surgeryAged; Aged 80 and over; COVID-19; Cohort Studies; Critical Care; Elective Surgical Procedures; Epidemics; Female; Humans; International Cooperation; Logistic Models; Male; Middle Aged; Neoplasms; Outcome Assessment Health Care; Postoperative Complications; SARS-CoV-2Cohort Studies0302 clinical medicineOperating theaterPostoperative Complicationscohort studiesNeoplasmsHealth caremiddle agedOutcome Assessment Health Care80 and overMedicineLungCancerCOVID-19/epidemiologyAged 80 and overOUTCOMESManchester Cancer Research CentrePulmonary ComplicationORIGINAL REPORTSMiddle AgedagedOncologyElective Surgical Procedures030220 oncology & carcinogenesisPneumonia & InfluenzaFemalePatient SafetyElective Surgical ProcedureLife Sciences & Biomedicine6.4 SurgeryCohort studyHumanmedicine.medical_specialtyelective surgical procedures/methodsLogistic ModelCritical CareAged; Aged; 80 and over; COVID-19; Cohort Studies; Critical Care; Elective Surgical Procedures; Epidemics; Female; Humans; International Cooperation; Logistic Models; Male; Middle Aged; Neoplasms; Outcome Assessment; Health Care; Postoperative Complications; SARS-CoV-2Clinical SciencesOncology and CarcinogenesisEpidemic[SDV.CAN]Life Sciences [q-bio]/Cancer-.cancer surgery ; COVID-19 ; SARS-CoV-2 pandemicepidemicsCOVIDSurg CollaborativeNOoutcome assessment health care/methods03 medical and health sciencesmaleSettore MED/28 - Malattie OdontostomatologicheClinical ResearchHumans1112 Oncology and CarcinogenesisOncology & CarcinogenesisElective surgeryEpidemicsElective Cancer Surgery in SARS-CoV-2 Elective Cancer Surgery in COVID-19 covid 19 sars-cov-2AgedScience & TechnologyElective Surgical Procedurebusiness.industrySARS-CoV-2PreventionResearchInstitutes_Networks_Beacons/mcrcEvaluation of treatments and therapeutic interventionsCOVID-191103 Clinical SciencesPneumoniaOdds ratiomedicine.diseaseHealth CarePneumoniaGood Health and Well Beingneoplasms/surgeryLogistic Modelscritical care/methodsEmergency medicinepostoperative complications/prevention & controlNeoplasmPostoperative ComplicationCohort Studiebusinessaged 80 and overSARS-CoV-2/physiologylogistic models
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct